PPF IPF SSc-ILDMechanism of ActionPrescribing information Previous Next FACE IPF HEAD ON and modify disease progression by slowing lung function decline Identify Patients With RA-ILD Who Can Benefit From OFEV 26/10/2022 | Author: Boehringer Ingelheim Document ID: PC-SA-101935 | Expiry Date: 18/08/2026 PPF PPF Identify Patients With RA-ILD Who Can Benefit From OFEV SSc-ILD AE Management Animation - Management of diarrhea SSc-ILD AE Management Animation - Management of nausea and vomiting How to understand and manage limited cutaneous SSc-ILD Safety Profile of OFEV Treatment of patients with PPF and CTD-ILD How to recognize ILD and PPF in patients with CTD Related content Read more PDF How to recognize ILD and PPF in patients with CTD PC-SA-102490 (May 2026 ) Download Opens in new tab Read more 3:43 Treatment of patients with PPF and CTD-ILD PC-SA-102492 (May 2026 ) Watch now Opens in new tab Read more PDF How to understand and manage limited cutaneous SSc-ILD PC-SA-102498 (May 2026 ) Download Opens in new tab Home Respiratory | Therapeutic Area Ofev Efficacy Identify Patients With RA-ILD Who Can Benefit From OFEV
Read more PDF How to recognize ILD and PPF in patients with CTD PC-SA-102490 (May 2026 ) Download Opens in new tab
Read more 3:43 Treatment of patients with PPF and CTD-ILD PC-SA-102492 (May 2026 ) Watch now Opens in new tab
Read more PDF How to understand and manage limited cutaneous SSc-ILD PC-SA-102498 (May 2026 ) Download Opens in new tab
